TABLE 1.

Demographic and clinical characteristics

		(N = 98) N (%)
Age at enrollment (mean ± SD)		60.12 ± 11.05 (range = 29–83)
BMI (mean ± SD)		29.70 ± 7.26 (range = 17.02–51.70)
Marital Status	Married/Committed relationship	70 (71.4%)
	Divorced	7 (7.1%)
	Single	8 (8.2%)
	Widowed	12 (12.2%)
	Other	1 (1.0%)
Number of children	None	8 (8.2%)
	One or two	50 (51.1%)
	Three or more	40 (40.8%)
Race	White/Caucasian	94 (95.9%)
	Other	4 (4.1%)
Education	Some high school (<11 years)	16 (16.3%)
	High school (11 years)	18 (18.4%)
	College (12–14)	28 (28.6%)
	Postsecondary (≥15)	36 (36.7%)
Currently employed	Yes	36 (36.7%)
	No	62 (63.3%)
Premenopausal	Yes	25 (25.5%)
	No	71 (72.4%)
	Unsure	2 (2.0%)
Surgery	Lumpectomy	40 (40.8%)
	Simple mastectomy	48 (49.0%)
	Modified radical mastectomy	10 (10.2%)
	Sentinel node biopsy	74 (75.5%)
	Axillary lymph node dissection	15 (15.3%)
Adjuvant therapy	Chemotherapy	22 (22.4%)
	Radiation	52 (53.1%)
	Trastuzumab	3 (3.6%)
Hormone therapy	Tamoxifen	19 (19.4%)
	Aromatase inhibitor	79 (80.6%)
T Stage	T1	67 (68.4%)
	T2	24 (24.5%)
	T3	6 (6.1%)
	T4	1 (1.0%)
Estrogen receptor positive	Yes	98 (100.0%)
	No	0 (0.0%)
Progesterone receptor positive	Yes	91 (92.9%)
	No	7 (7.1%)
HER2 positive	Yes	5 (5.1%)
	No	93 (94.9%)

Caucasians made up 95.9% of the sample. On average, participants were 60.1 years old (range 29–83) and had 13.6 years of education (range 7–25).

Abbreviations: BMI, Body Mass Index; HER2, human epidermal growth factor receptor 2.